SESSION TYPE: COPD Posters II
PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM
PURPOSE: A new method of analyzing a pulse oximeter waveform (RRoxi algorithm) allows continuous non-invasive respiratory rate monitoring. The RRoxi algorithm uses respiratory-induced modulations in the photoplethysmogram secondary to changes in hemodynamic and autonomic activity throughout the respiratory cycle. Patients with chronic obstructive pulmonary disease (COPD) may exhibit abnormal cardiorespiratory interactions that could influence the modulations used by RRoxi to extract respiratory rate. We therefore sought to determine the accuracy of RRoxi in patients with COPD.
METHODS: With IRB approval and patient consent, we enrolled 22 non-intubated patients diagnosed with COPD (age: 61.8 ± 11.8 yr; BMI: 28.6 ± 7.7 kg/m2, 4 female/ 18 male). During an observational study period of ~20 min on the general care floor or in the ICU, photoplethysmogram data were acquired from an index finger using a pulse oximetry sensor. Nasal/oral capnography waveforms were acquired simultaneously to determine a reference respiratory rate. Respiratory rate values were computed offline by RRoxi. Accuracy was calculated as root mean square deviation (RMSD) between RRoxi and the reference respiratory rate, and Pearson correlation coefficients were computed to assess their relationship.
RESULTS: RRoxi determined a respiratory rate value 93% of the monitoring period, yielding a total of 4,917 paired observations (RRoxi values and the capnography-based reference). Mean and range of the reference respiratory rate were 17.6 ± 4.4 and 8.1 to 32 breaths per minute, respectively. The mean difference between the reference and RRoxi respiratory rate measurements was 0.7 ± 1.6 breaths per minute. The accuracy of RRoxi was 1.7 breaths per minute, as measured by RMSD and the agreement between RRoxi and the reference was R2=0.87.
CONCLUSIONS: These results demonstrate that in patients with COPD, the RRoxi algorithm was accurate to within 1.7 breaths per minute (RMSD) and able to determine a respiratory rate value during 93% of the monitoring period.
CLINICAL IMPLICATIONS: These accuracy and availability results suggest that RRoxi should be clinically acceptable to provide continuous non-invasive respiratory rate monitoring in similar hospitalized patients.
DISCLOSURE: Michael Mestek: Employee: Covidien Respiratory & Monitoring Solutions Scientist
Paul Addison: Employee: Covidien Respiratory & Monitoring Solutions Scientist
Anna-Maria Neitenbach: Employee: Covidien Respiratory & Monitoring Solutions Research Associate.
Sergio Bergese: Other: Dr. Bergese received financial funding for data collection on hospitalized patients for this study.
Scott Kelley: Employee: Dr. Kelley is the Chief Medical Officer at Covidien Respiratory & Monitoring Solutions
No Product/Research Disclosure InformationCovidien, Boulder, CO